News

Designed for Human Insulin Detection We are proud to introduce the Insulin MBeads Assay (10-1371-01), a high-throughput solution for accurate and efficient quantification of human insulin in vitro. De...

In 2024, we achieved 33 percent growth, bringing our total growth to 70 percent over the past three years. This reflects our long-term focus on delivering high-quality bioanalytical services and innov...

Which insulin assay should you choose? Selecting the correct insulin assay is essential for obtaining accurate and reliable results. Whether you are analyzing insulin in plasma, serum, cell culture me...

Mercodia recently completed a comprehensive assessment of our sustainability practices with EcoVadis, a global leader in sustainability evaluations. As part of our commitment to sustainability, we con...

Building a Comprehensive Data Transfer Agreement: Best practices and hands-on experience Wednesday, October 30, 2024 | 1:15 pm EDT (NA) / 6:15 pm CET | 30 min, or on-demand Don’t miss our AAPS-h...

Advances in MASLD and MASH Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where excessive fat accumulates in liver cells. It has been observed that approximately 30% o...

GLP-1 and GIP: Mercodia products in the spotlight Metabolic-related diseases, including obesity and types 1 and 2 diabetes, among others, have become major health problems worldwide, with a rapid incr...

Biomarkers stand out among the innovations driving the acceleration of drug development. This eBook offers scientific insights and applications that any scientist can benefit from. Discover how Univer...

At Mercodia, we are constantly striving to enhance your experience with our products. Today, we are thrilled to announce significant updates that reflect our commitment to sustainability and customer ...